Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24245886 | 0.97 | ALDH1A1 (0.30) | ALDH1A1TP53CYP3A4TSHRACHE | |
| SCHEMBL14123523 | 0.88 | ALDH1A1 (0.30) | ALDH1A1TP53CYP3A4TSHRACHE | |
| SCHEMBL27445264 | 0.86 | GAA (0.31) | — | |
| SCHEMBL27434108 | 0.82 | NPC1 (0.31) | — | |
| Hydrazine SCHEMBL4470399 | 0.82 | — | — | |
| Hydrazine SCHEMBL28654430 | 0.79 | HSP90AB1 (0.31) | — | |
| SCHEMBL11802553 | 0.77 | HRH4 (0.34) | — | |
| SCHEMBL17467255 | 0.76 | HRH4 (0.36) | — | |
| SCHEMBL13333647 | 0.76 | — | — | |
| SCHEMBL2614743 | 0.73 | HRH4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-10967071-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | Bicyclerd Limited (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200283482-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-10 | — | — | US | disclosed |
| WO-2020160222-A2 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20170040552-A1 | Organic Electroluminescent Materials and Devices | UNIVERSAL DISPLAY CORPORATION | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | STING1, BID, VIP | ALDH1A1 4871/4885TP53 745/4885CYP3A4 4418/4885 |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | ALDH1A1 4676/4885TP53 280/4885CYP3A4 4319/4885 |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | VIP, NGLY1, GRPR | ALDH1A1 4676/4885TP53 280/4885CYP3A4 4319/4885 |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | ALDH1A1 98/4885TP53 1313/4885CYP3A4 1015/4885 |
| US-10967071-B2 | Drug-conjugates, conjugation methods, and uses thereof | PAICS, CES2, DNPEP | ALDH1A1 160/4885TP53 2257/4885CYP3A4 406/4885 |
| US-20170040552-A1 | Organic Electroluminescent Materials and Devices | OCIAD2, OCIAD1, OSBP | ALDH1A1 2050/4885TP53 3138/4885CYP3A4 2683/4885 |
| US-20200283482-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | PRRC2A, GRPR, QRFPR | ALDH1A1 3405/4885TP53 2683/4885CYP3A4 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.